ADJUBIL: Phase II Study of Adjuvant Immunotherapy with STRIDE Regimen With/Without Capecitabine in Biliary Tract Cancers-Reference-Cited by-同舟云学术

ADJUBIL: Phase II Study of Adjuvant Immunotherapy with STRIDE Regimen With/Without Capecitabine in Biliary Tract Cancers

Published:2024-02 Issue:6 Volume:20 Page:307-315
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncol.

Author:

Goetze Thorsten¹²,Gonzalez-Carmona Maria A³,Kochen Lisa²,Agaoglu Nihat Bugra²^ORCID,Al-Batran Salah-Eddin¹²^ORCID,Habibzada Timorshah¹,Pons Miriam²,Brunner Marius⁴,Ettrich Thomas J⁵,Köhne Claus-Henning⁶,Roderburg Christoph⁷^ORCID,Modest Dominik⁸

Affiliation:

1. Krankenhaus Nordwest, University Cancer Center Frankfurt, Steinbacher Hohl 2-26, 60488Frankfurt, Germany

2. Frankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Steinbacher Hohl 2-26, 60488Frankfurt, Germany

3. Universitätsklinikum Bonn, Venusberg-Campus 1, 53127BonnGermany

4. Universitätsklinikum Göttingen, Robert Koch Straße 40, 37075Göttingen, Germany

5. Universitätsklinikum Ulm, Albert-Einstein-Allee 23, 89081Ulm, Germany

6. Department of Gynaekology, Klinikum Oldenburg AöR, Rahel-Straus-Straße 10, 26133Oldenburg, Germany

7. Universitätsklinikum Düsseldorf, Moorenstraße 5, 40225Düsseldorf, Germany

8. Department of Hematology, Oncology, and Cancer Immunology (CVK) Charité Berlin, Augustenburger Platz 1 Ostring 1, 13353Berlin, Germany

Funder

AstraZeneca

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.2217/fon-2023-0961

Reference27 articles.

1. The epidemiological trends of biliary tract cancers in the United States of America

2. A Systematic Review and Network Meta-Analysis of Adjuvant Therapy for Curatively Resected Biliary Tract Cancers

3. Systematic review with network meta-analysis: adjuvant therapy for resected biliary tract cancer

4. Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study

5. Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial